Kalaris Therapeutics, Inc.
KLRS
$4.16
$0.081.84%
NASDAQ
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 16.93% | 0.80% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 9.55% | -15.23% | |||
| Operating Income | -9.55% | 15.23% | |||
| Income Before Tax | -8.58% | 15.94% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -8.58% | 15.94% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -8.58% | 15.94% | |||
| EBIT | -9.55% | 15.23% | |||
| EBITDA | -9.56% | 15.30% | |||
| EPS Basic | 10.96% | 19.20% | |||
| Normalized Basic EPS | 10.96% | 19.19% | |||
| EPS Diluted | 10.96% | 19.20% | |||
| Normalized Diluted EPS | 10.96% | 19.19% | |||
| Average Basic Shares Outstanding | 21.95% | 4.02% | |||
| Average Diluted Shares Outstanding | 21.95% | 4.02% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||